Martyn Jones on Muck Rack

Martyn Jones

Toronto
As seen in: The Bulwark, Color Research & Application, CorranCast, Wiley Online Library, Journal of Clinical Pathology, Substack, Sydney Morning Herald, The Conversation, The Sunday Age, New Zealand Herald, Science Magazine and
Senior editor, @BulwarkOnline. American in Canada, writer. Dad newsletter: martynwendell.substack.com/
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Martyn

Contact Martyn, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Herbert Smith Freehills Kramer advises Coca-Cola HBC on its acquisition of CCBA

|
By Martyn Jones, Thomas Vaughan, Mehdi Tedjani, Arijeet Mukherjee
| Herbert Smith Freehills Kramer
Leading global law firm Herbert Smith Freehills Kramer has advised Coca-Cola HBC AG (Coca-Cola HBC) on its acquisition of a 75% shareholding in Coca-Cola Beverages Africa Pty Ltd (CCBA) from The Coca-Cola Company and Gutsche Family Investments Pty Ltd for a combined purchase price of US$2.6 billion, implying an equity value for 100% of CCBA at US$3.4 billion.
Open in Who Shared Issue with article?

Biopharma M&A Activity - Strategics Continue To Lead The Way

|
By Alan F Montgomery, Martyn Jones, Nikesh Arya, Lerryn Martin
| Mondaq
Alan Montgomery’s articles from Herbert Smith Freehills Kramer LLP are most popular: within Food, Drugs, Healthcare and Life Sciences topic(s) in United Kingdom with readers working within the Pharmaceuticals & BioTech industries Herbert Smith Freehills Kramer LLP are most popular: within Food, Drugs, Healthcare, Life Sciences, Environment and Coronavirus (COVID-19) topic(s) As we entered 2025, we were hopeful for a more upbeat year for pharma M&A activity but, with headwinds still swirling,...
Open in Who Shared Issue with article?

Biopharma M&A Activity - As We Enter The Latter Months Of 2025, Strategics Continue To Lead The Way

|
By Alan F Montgomery, Martyn Jones, Nikesh Arya, Lerryn Martin
| Mondaq
As we entered 2025, we were hopeful for a more upbeat year for pharma M&A activity but, with headwinds still swirling, a dramatic change of pace seemed unlikely. Indeed, with further uncertainty for the sector in what was already a disrupted business environment, 2025 so far provides a mixed tale. On the one hand, deal volume has remained at a similar pace to 2024 but, in more promising signs, total deal value in the sector is on the rise and we are seeing more higher value deals.
Open in Who Shared Issue with article?
See all 125 licensed articles (138 Total)

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Get in touch with Martyn

Contact Martyn, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified